The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson's disease therapy

Brain Research

Volumn 1622, Issue , 2015, Pages 127-136

  Lazzara, Carol A ^a   Riley, Rebeccah R ^b   Rane, Anand ^b   Andersen, Julie K ^b   Kim, Yong Hwan ^a  

^a DELAWARE STATE UNIVERSITY   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

AIM; Calpain 1; Combination therapy; MPTP; Neurodegenerative disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALPAIN 1; CALPAIN 2; CARBIDOPA PLUS LEVODOPA; HISTONE ACETYLTRANSFERASE; LITHIUM; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; ANTIPARKINSON AGENT; CALPAIN; CALPAIN 1 PROTEIN, RAT; CAPN1 PROTEIN, MOUSE; CAPN2 PROTEIN, MOUSE; CARBIDOPA; LEVODOPA; LITHIUM CHLORIDE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE METABOLISM; DOWN REGULATION; DYSKINESIA; ENZYMATIC ASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEREOMETRY; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN STEM; C57BL MOUSE; CELL LINE; COMBINATION DRUG THERAPY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN STEM; CALPAIN; CARBIDOPA; CELL DEATH; CELL LINE; CORPUS STRIATUM; DOPAMINERGIC NEURONS; DRUG THERAPY, COMBINATION; HISTONE ACETYLTRANSFERASES; LEVODOPA; LITHIUM CHLORIDE; MALE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; RATS; TYROSINE 3-MONOOXYGENASE;

EID: 84940543768     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.06.018     Document Type: Article

References (42)

1. T. Abel, and R.S. Zukin Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders Curr. Opin. Pharmacol. 8 1 2008 57 64 Review
2. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 2001 448 458
3. D. Alvira, I. Ferrer, J. Gutierrez-Cuesta, B. Garcia-Castro, M. Pallas, and et al. Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease Parkinsonism Relat. Disord. 14 2008 309 313
4. S.B. Blunt, P. Jenner, and C.D. Marsden The effect of l-dopa and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography Neuroscience 43 1 1991 95 110
5. V. Bogaerts, J. Theuns, and C. van Broeckhoven Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav. 7 2008 129 151
6. M. Brandt-Christensen, K. Kvist, F.M. Nilsson, P.K. Andersen, and L.V. Kessing Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study J. Neurol. Neurosurg. Psychiatry 77 2006 781 783
7. A. Camins, N. Crespo-Biel, F. Junyent, E. Verdaguer, A.M. Canudas, and M. Pallàs Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium Curr. Drug Metab. 10 5 2009 433 447 Review
8. G.G. Celesia, and W.M. Wanamaker l-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease Dis. Nerv. Syst. 37 3 1976 123 125
9. L. Chagniel, C. Robitaille, M. Lebel, and M. Cyr Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model Neurobiol. Dis. 45 2012 645 655
10. C.E. Coffey, D.R. Ross, E.L. Ferren, J.L. Sullivan, and C.W. Olanow Treatment of the "on-off" phenomenon in Parkinsonism with lithium carbonate Ann. Neurol. 12 1982 375 379
11. N. Crespo-Biel, A. Camins, M. Pallas, and A.M. Canudas Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro Neuropharmacology 56 2009 422 428
12. S.J. Crocker, P.D. Smith, V. Jackson-Lewis, W.R. Lamba, S.P. Hayley, and et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease J. Neurosci. 23 2003 4081 4091
13. M.C. de Rijk, L.J. Launer, K. Berger, M.M. Breteler, J.F. Dartigues, and et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group Neurology 54 2000 S21 S23
14. R. Farah, R. Khamisy-Farah, T. Amit, M.B. Youdim, and Z. Arraf Lithium's gene expression profile, relevance to neuroprotection A cDNA microarray study Cell. Mol. Neurobiol. 33 3 2013 411 420
15. P.O. Fernagut, E. Diguet, N. Stefanova, M. Biran, G.K. Wenning, and et al. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation Neuroscience 114 2002 1005 1017
16. M. Ferrucci, A. Spalloni, A. Bartalucci, E. Cantafora, F. Fulceri, and et al. A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium Neurobiol. Dis. 37 2010 370 383
17. E.G. Jorda, E. Verdaguer, A.M. Canudas, A. Jimenez, S. Garcia de Arriba, and et al. Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium Neuroscience 134 2005 1001 1011
18. N. Kanagaraj, H. Beiping, S.T. Dheen, and S.S. Tay Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins Neuroscience 11 272 2014 167 179
19. Y.H. Kim, A. Rane, S. Lussier, and J.K. Andersen Lithium protects against oxidative stress-mediated cell death in alpha-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease J. Neurosci. Res. 89 2011 1666 1675
20. Y.H. Kim, S. Lussier, A. Rane, S.W. Choi, and J.K. Andersen Inducible dopaminergic glutathione depletion in an alpha-synuclein transgenic mouse model results in age-related olfactory dysfunction Neuroscience 172 2011 379 386
21. S.H. Koh, C. Song, M.Y. Noh, H.Y. Kim, K.Y. Lee, and et al. Inhibition of glycogen synthase kinase-3 reduces l-dopa-induced neurotoxicity Toxicology 247 2008 112 118
22. E. Kontopoulos, J.D. Parvin, and M.B. Feany Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity Hum. Mol. Genet. 15 20 2006 3012 3023
23. G. Kusakawa, T. Saito, R. Onuki, K. Ishiguro, T. Kishimoto, and et al. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25 J. Biol. Chem. 275 2000 17166 17172
24. X. Li, G.N. Bijur, and R.S. Jope Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection Bipolar Disord. 4 2002 137 144
25. C.A. Lieu, C.M. Dewey, S.J. Chinta, A. Rane, S. Rajagopalan, S. Batir, Y.H. Kim, and J.K. Andersen Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model Brain Res. 3 1591 2014 111 117
26. G. McColl, D.W. Killilea, A.E. Hubbard, M.C. Vantipalli, S. Melov, and G.J. Lithgow Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans J. Biol. Chem. 283 1 2008 350 357
27. A. Mouatt-Prigent, J.O. Karlsson, Y. Agid, and E.C. Hirsch Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73 1996 979 987
28. R. Nciri, F. Desmoulin, M.S. Allagui, J.C. Murat, A.E. Feki, and et al. Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress Int. J. Neuropsychopharmacol. 16 2 2013 365 376
29. R. Pies Have we undersold lithium for bipolar disorder? J. Clin. Psychopharmacol. 22 2002 445 449
30. N. Riadh, M.S. Allagui, E. Bourogaa, C. Vincent, F. Croute, and et al. Neuroprotective and neurotrophic effects of long term lithium treatment in mouse brain Biometals 24 2011 747 757
31. A.M. Rice, and A.C. Sartorelli Inhibition of 20S and 26S proteasome activity by lithium chloride: impact on the differentiation of leukemia cells by all-trans retinoic acid J. Biol. Chem. 276 2001 42722 42727
32. M. Riverol, C. Ordóñez, M. Collantes, C. DiCaudo, I. Peñuelas, J. Arbizu, I. Marcilla, and M.R. Luquin Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway Neurobiol. Dis. 62 2014 250 259
33. C. Rouaux, N. Jokic, C. Mbebi, S. Boutillier, J.P. Loeffler, and A.L. Boutillier Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration 22 24 2003 6537 6549 EMBO J. 22 24 2003 6537 6549
34. R.N. Saha, and K. Pahan HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis Cell Death Differ. 13 4 2006 539 550 Review
35. H.C. Shen, J.Y. Li, and Y.K. Lo Lithium intoxication-induced acute parkinsonism complicated with hyperparathyroidism and nephrogenic diabetes insipidus: report of a case Acta Neurol. Taiwan. 16 2007 231 233
36. J.Y. Shin, H.J. Park, Y.H. Ahn, and P.H. Lee Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study J. Neurochem. 111 2009 1042 1050
37. A. Siddiqui, S.J. Chinta, J.K. Mallajosyula, S. Rajagopolan, I. Hanson, A. Rane, S. Melov, and J.K. Andersen Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease Free Radic. Biol. Med. 53 4 2012 993 1003
38. D.F. Smith Antagonistic effect of lithium chloride on l-dopa-induced locomotor activity in rats Pharmacol. Res. Commun. 8 1976 575 579
39. P.D. Smith, M.P. Mount, R. Shree, S. Callaghan, R.S. Slack, H. Anisman, I. Vincent, X. Wang, Z. Mao, and D.S. Park Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2 J. Neurosci. 26 2 2006 440 447
40. J. Wajsbort, A. Dorner, and E. Wajsbort A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson's disease Curr. Med. Res. Opin. 5 9 1978 695 708
41. L. Yao, W. Li, H. She, J. Dou, L. Jia, Y. He, Q. Yang, J. Zhu, N.L. Cápiro, D.I. Walker, K.D. Pennell, Y. Pang, Y. Liu, Y. Han, and Z. Mao Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects J. Biol. Chem. 287 41 2012 34246 34255
42. M.B. Youdim, and Z. Arraf Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax Neuropharmacology 46 2004 1130 1140